血清细胞因子IL-17 与脱髓鞘性神经病多发性硬化相关性的研究: Meta分析

目的:系统评价血清细胞因子白细胞介素17(Interluekin-17,IL-17)与脱髓鞘性神经病多发性硬化(Multiple sclerosis,MS)的相关性。方法:全面检索PubMed、SpringerLink、Embases、OVID、中国期刊全文数据库(CNKI)、维普中文科技期刊全文数据库(VIP)、中国生物医学文献服务系统(SinoMed)、万方医药期刊数据库(WAN FANG)等。中文检索词以“多发性硬化冶和“白细胞介素17 或Interleukin-17 或IL-17冶为并列检索词,英文检索词为“multiple sclerosis or MS冶and“Interleukin-17 orIL-17”。软件版本为Review Manager 5.3,检索年限限定2000 年1 月1 日到2017 年3 月10 日,检索语言不限。结果:最终纳入8 个病例对照研究,发表年份在2008 ~2016 年间,共纳入544 例研究对象,其中MS 组299 例,对照组245 例,合并分析结果显示:合并效应加权均差WMD=38.65,95% 可信区间:(18.66,58.63),表明总体合并结果有显著性差异,即MS 组血清IL-17水平明显高于对照组。结论:MS 患者血清IL-17 水平明显高于健康人群,IL-17 水平可能作为诊断MS 的一个新的生物标志物和有效防治MS 的一个新靶点。

Correlation between serum cytokine IL-17 and demyelinating neuropathy multiple sclerosis:a Meta-analysis

Objective: To evaluate the association with serum Interleukin-17 ( IL-17 ) and multiple sclerosis ( MS) systematically evaluated.Methods: The retrieval words of "multiple sclerosis or MS" and "interleukin-17 or IL-17" were searched in PubMed,SpringerLink,Embases,OVID,China National Knowledge infrastructure (CNKI),Chinese VIP database,Chinese Biomedical Literature Database (CBM),Wan Fang Database through computer.Review Manager 5.3.was selected as the software edition.The time frame was ranged from January 1,2000 to March 10,2017.The language was not restricted.Results: Eventually 8 case-control studies were included with 544 cases.We found that the serum IL-17 level was associated with MS according to the weighted mean difference and 95% confidence interval (WMD = 38.65;95% CI:18.66,58.63),which had significant difference in statistics.Conclusion: The serum IL-17 level increases the risk of MS,suggesting that the serum IL-17 level can be used as a predictive biomarker for MS development and a target for MS effective prevention and treatment.